As part of our ‘meet the team’ series, Admescope welcomes Leah Haydock, a new US-based member of the Business Development team. With over 15 years of experience in international business, sales and marketing at companies including Evans Medical, Smith & Nephew and Cynosure, Leah is excited to join the company and put her background in pharmacology to good use.
Leah recently visited the Admescope facility in Oulu, Finland for an intensive training period; meeting the scientific teams, visiting the labs and learning about our process of providing high-quality scientific and technical data that customers rely on for their decision making.
Leah is originally from the UK but has lived in the US for over 20 years, including Maine and New Hampshire before settling in Boston, Massachusetts. Outside of work, Leah enjoys photography, eating out in Boston’s many restaurants, and swimming in New England lakes. Although she hung up her skis a few years ago, she was persuaded to don them again for some traditional Finnish ‘training’ of forest skiing in unbroken snow followed by cooking sausages over a fire!
In her role of Director of Business Development for North America, Leah is looking forward to working with existing US customers of Admescope and also introducing our tailor-made ADME-Tox services to new customers, including the ever-expanding Biotech industry in Boston and Cambridge, MA. The US is just one of the 30 countries serviced by Admescope. Our teams of dedicated and specialized scientists in Finland, Sweden and Netherlands have completed numerous studies in drug metabolism, drug interactions, quantitative bioanalysis, biologics including ADC characterization to AAALAC accredited in vivo PK studies, metabolites in safety testing (MIST) and more.
“Admescope offers an impressive and broad portfolio of ADME-Tox services, from high-throughput early ADME profiling to tailor-made complex studies. As a resident of Boston for the last 5 years, I see almost never-ending construction of new biotech, life science and pharmaceutical buildings from Kendall Sq to Fort Point and know this is such an exciting time for drug discovery. I’m excited to introduce our CRO services locally in Boston and Cambridge and further afield” said Leah.
Leah is especially looking forward to a collaborative working relationship with Bart DeCorte and Chris Teleha who are responsible for business development for Symeres, the parent company of Admescope. ‘We are delighted to have Leah join our organization. Leah’s background nicely compliments our medicinal chemistry and drug development skills and allows us to offer the full spectrum of synthesis and ADME-Tox expertise to our clients.” said Bart DeCorte.
On June 8-9th 2022, Leah will attend the Precision in Drug Discovery and Preclinical Summit in Boston, MA with colleagues Miia Kovalainen, Head of Business Development for Admescope and Russell Thomas, Head of Business Development for Symeres. If you are a biotech or pharma business on the East Coast, we’d love to learn more about your ADME-Tox needs and share how our customer-focused approach can save you time, development costs and reduce late failures. Reach out to set up a meeting today!
